<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574080</url>
  </required_header>
  <id_info>
    <org_study_id>2006-15</org_study_id>
    <nct_id>NCT00574080</nct_id>
  </id_info>
  <brief_title>UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide</brief_title>
  <official_title>UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose
      chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve
      myeloma response and acquire longer survival for participants.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Up to 3 years 8 months</time_frame>
    <description>Time from study registration until disease progression or death.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interim/Maintenance Dexamethasone</intervention_name>
    <description>20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Dex</other_name>
    <other_name>Dexamethasone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction/Consolidation Dexamethasone</intervention_name>
    <description>40 mg Days 1-4</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Dex</other_name>
    <other_name>Dexamethasone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction/Consolidation Cisplatin</intervention_name>
    <description>10 mg/m2 by continuous infusion Days 1-4</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction/Consolidation Adriamycin</intervention_name>
    <description>10 mg/m2 by continuous infusion Days 1-4</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>InductionConsolidation Cyclophosphamide</intervention_name>
    <description>400 mg/m2 by continuous infusion Days 1-4</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction/Consolidation Etoposide</intervention_name>
    <description>40 mg/m2 by continuous infusion Days 1-4</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction Pegfilgrastim</intervention_name>
    <description>6 mg Days 6 and 13</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Dexamethasone</intervention_name>
    <description>20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Cisplatin</intervention_name>
    <description>20 mg/m2 by continuous infusion Days -3 and -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Adriamycin</intervention_name>
    <description>20 mg/m2 by continuous infusion Days -3 and -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Cyclophosphamide</intervention_name>
    <description>800 mg/m2 by continuous infusion Days -3 and -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Etoposide</intervention_name>
    <description>80 mg/m2 by continuous infusion Days -3 and -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 Melphalan</intervention_name>
    <description>50 mg/m2 Days -2 and -1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 and 2 Pegfilgrastim</intervention_name>
    <description>6 mg Day +6</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Peripheral Blood Stem Cell Transplant (ASCT)</intervention_name>
    <description>Day 0</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 2 Carmustine</intervention_name>
    <description>300 mg/m2 Day -5</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 2 Etoposide</intervention_name>
    <description>200 mg/m2 Days -5, -4, -3, -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 2 Cytarabine</intervention_name>
    <description>400 mg/m2 Days -5, -4, -3, -2</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 2 Melphalan</intervention_name>
    <description>140 mg/m2 Day -1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 2 Dexamethasone</intervention_name>
    <description>20 mg Days -5, -4, -3, -2, +4, +5, +6, +7</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 and 2 Bortezomib</intervention_name>
    <description>1 mg/m2 Days -4, -1, +3, +7</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplant 1 and 2 Thalidomide</intervention_name>
    <description>200 mg Days -4 to +5</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic multiple myeloma, sensitive or refractory to at least one
             prior line of chemotherapy.

          -  Karnofsky performance score &gt; 60%, unless due to MM.

          -  Patients must be &lt;75 years of age at the time of registration.

          -  Patient must not have had a prior auto- or allotransplant.

          -  Patient must have signed an IRB-approved informed consent and understand the
             investigational nature of the study.

          -  Negative serology for HIV.

          -  Baseline biopsies and laboratory studies are to be completed within 35 days of
             registration, within 60 days for scans and radiological studies; patients must not
             have a history of severe chronic obstructive or chronic restrictive pulmonary disease.
             Patients must have adequate pulmonary function studies &gt; 50% of predicted on
             mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) &gt; 50% of predicted.
             Patients unable to complete pulmonary function tests because of myeloma-related chest
             pain, must have a high resolution CT scan of the chest and must also have acceptable
             arterial blood gases defined as P02 greater than 70.

          -  Patients with recent (&lt; 6 months) myocardial infarction, unstable angina, difficult to
             control congestive heart failure, uncontrolled hypertension, or difficult to control
             cardiac arrhythmias are ineligible. Ejection fraction by ECHO or MUGA must be &gt; 40%
             and must be performed within 60 days prior to registration, unless the patient has
             received chemotherapy within that period of time (dexamethasone and thalidomide
             excluded), in which case the LVEF must be repeated.

          -  No prior malignancy is allowed except for adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
             been disease free for at least three years. Prior malignancy is acceptable provided
             there has been no evidence of disease within the three-year interval or if the
             malignancy is considered much less life threatening than the myeloma.

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy documented within one week of registration. Women/men of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method.

          -  Patients must be able to receive full doses of D PACE, in the opinion of the treating
             investigator, with the exception that patients with creatinine clearance 30-50 ml/min
             will receive only 50% of the cisplatin dose.

        Exclusion Criteria:

          -  Fever or active infection requiring intravenous antibiotic, defined as fever or
             antibiotics within 72 hours from baseline.

          -  Severe renal dysfunction, defined as a creatinine &gt; 3mg/dl or a creatinine clearance
             of &lt; 30ml/min.

          -  Significant neurotoxicity, defined as grade &gt; 3 neurotoxicity per NCI Common Toxicity
             Criteria (See Appendix).

          -  Platelet count &lt; 100,000/mm^3, or ANC &lt; 1,000/μl

          -  POEMS Syndrome.

          -  Clinically significant hepatic dysfunction as noted by direct bilirubin or AST &gt;3
             times the upper normal limit or clinically significant concurrent hepatitis.

          -  New York Hospital Association (NYHA) Class III or Class IV heart failure.

          -  Myocardial infarction within the last 6 months.

          -  Patients with a history of treatment for clinically significant ventricular cardiac
             arrhythmias.

          -  Poorly-controlled hypertension, diabetes mellitus, or other serious medical illness or
             psychiatric illness that could potentially interfere with the completion of treatment
             according to this protocol.

          -  Prior adriamycin exposure &gt;450 mg/m^2

          -  Prior exposure to thalidomide which resulted in severe toxicity requiring drug
             discontinuation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frits van Rhee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <results_first_submitted>May 4, 2011</results_first_submitted>
  <results_first_submitted_qc>June 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2011</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants are myeloma patients who have already received one or more treatment regimens and are seen at our facility</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>VTD + DPACE/Melphalan</title>
          <description>Velcade, thalidomide, and dexamethasone + Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
        <group group_id="P2">
          <title>DPACE/Melphalan</title>
          <description>Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VTD + DPACE/Melphalan</title>
          <description>Velcade, thalidomide, and dexamethasone + Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
        <group group_id="B2">
          <title>DPACE/Melphalan</title>
          <description>Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.2" spread="5.01"/>
                    <measurement group_id="B2" value="59" spread="8.67"/>
                    <measurement group_id="B3" value="57.6" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event Free Survival</title>
        <description>Time from study registration until disease progression or death.</description>
        <time_frame>Up to 3 years 8 months</time_frame>
        <population>no analysis, participants either died or were withdrawn by PI. study terminated with &lt;10% of target accrual enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival</title>
          <description>Time from study registration until disease progression or death.</description>
          <population>no analysis, participants either died or were withdrawn by PI. study terminated with &lt;10% of target accrual enrolled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VTD + DPACE/Melphalan</title>
          <description>Velcade, thalidomide, and dexamethasone + Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
        <group group_id="E2">
          <title>DPACE/Melphalan</title>
          <description>Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, and Etoposide &amp; Melphalan</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>progressive disease</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>cardiac failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>progressive disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <description>no cause listed</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <description>infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <description>sepsis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>secondary malignancy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination led to small numbers of subjects to be analyzed. Less than 10% of the target accrual were enrolled before termination of study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nathan M. Petty</name_or_title>
      <organization>University of Arkansas for Medical Sciences, Myeloma Institute</organization>
      <phone>501-526-6990 ext 2461</phone>
      <email>PettyNathanM@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

